Structure Therapeutics Inc. (GPCR) Financial Statements (2026 and earlier)

Company Profile

Business Address 601 GATEWAY BLVD SUITE 900
SOUTH SAN FRANCISCO, CA 94080
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)
Annual | Quarterly

3/31/2026
MRQ
12/31/2025
12/31/2024
12/31/2023
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:1,446,200,000883,500,000467,300,000
Cash and cash equivalent799,623,000169,510,000129,792,000
Short-term investments646,574,000714,008,000337,531,000
Other undisclosed cash, cash equivalents, and short-term investments3,000(18,000)(23,000)
Receivables 100,000,000  
Other undisclosed current assets24,103,0007,711,0006,308,000
Total current assets:1,570,303,000891,211,000473,608,000
Noncurrent Assets
Operating lease, right-of-use asset6,245,0003,535,0005,136,000
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization6,653,0003,478,0003,228,000
Other noncurrent assets717,0005,106,00045,000
Total noncurrent assets:13,615,00012,119,0008,409,000
TOTAL ASSETS:1,583,918,000903,330,000482,017,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities32,212,00021,838,00012,813,000
Accounts payable13,864,0008,024,0004,742,000
Accrued liabilities18,348,00013,814,0008,071,000
Other undisclosed current liabilities31,073,00014,183,00011,927,000
Total current liabilities:63,285,00036,021,00024,740,000
Noncurrent Liabilities
Liabilities, other than long-term debt4,256,0002,466,0004,311,000
Other liabilities647,000302,000298,000
Operating lease, liability3,609,0002,164,0004,013,000
Total noncurrent liabilities:4,256,0002,466,0004,311,000
Total liabilities:67,541,00038,487,00029,051,000
Equity
Equity, attributable to parent1,516,377,000864,843,000452,966,000
Common stock21,00017,00014,000
Additional paid in capital1,985,602,0001,193,010,000659,003,000
Accumulated other comprehensive income (loss)1,054,000914,000521,000
Accumulated deficit(470,300,000)(329,098,000)(206,572,000)
Total equity:1,516,377,000864,843,000452,966,000
TOTAL LIABILITIES AND EQUITY:1,583,918,000903,330,000482,017,000

Income Statement (P&L) (USD)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
Operating expenses(176,560,000)(158,228,000)(102,775,000)
Operating loss:(176,560,000)(158,228,000)(102,775,000)
Loss from continuing operations before equity method investments, income taxes:(176,560,000)(158,228,000)(102,775,000)
Other undisclosed income from continuing operations before income taxes35,873,00036,012,00013,391,000
Loss from continuing operations before income taxes:(140,687,000)(122,216,000)(89,384,000)
Income tax expense(515,000)(310,000)(236,000)
Net loss available to common stockholders, diluted:(141,202,000)(122,526,000)(89,620,000)

Comprehensive Income (USD)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
Net loss:(141,202,000)(122,526,000)(89,620,000)
Comprehensive loss:(141,202,000)(122,526,000)(89,620,000)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent140,000393,000631,000
Comprehensive loss, net of tax, attributable to parent:(141,062,000)(122,133,000)(88,989,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: